舒利迭吸入剂对56例稳定期慢性阻塞性肺疾病患者的临床疗效观察被引量：2

The clinic efficacy of seretide in 56 patients with stable chronic obstructive pulmonary disease

下载PDF

导出

摘要目的观察舒利迭干粉剂对慢性稳定期慢性阻塞性肺疾病(COPD)的疗效。方法将56例处于慢性缓解期的COPD患者,随即分成实验组和对照组。对照组给予常规治疗,实验组在此基础上给予吸入舒利迭(50/250)。记录治疗前后的患者症状缓解情况,肺功能和血气分析指标。结果实验组的总有效率显著高于对照组,两组疗效比较差异有统计学意义(P<0.05)。结论应用舒利迭(50/250)治疗慢性缓解期COPD,能显著改善肺功能,动脉血气指标,患者依从性好,副反应少。 Objective To investigate the effect of treatment using seretide on patient with stable chronic obstructive pulmonary disease. Methods 56 patients with stable COPD after hospital discharge were randomly divided into treatment and control groups. The contrlol groups was given conventional treatment, the treatment group was given seretide（50/250） on the basis of conventional treatment. The parameters of lung function and clinical effect, arterial blood, gases were measured before and after treatment. Results The efficient of the treatment group significantly higher than that of the control group. Efficacy difference between the two groups was significant（P 〈0. 01 ）. Conclusion Application of Seretide in the treatment of stability during COPD can siginficantly improve lung function and arterial blood gases indictions,The patients has good compliance and little side effect.

作者陈文韬杜坤

机构地区湖北省鄂州市中心医院呼吸内科

出处《中国实用医药》 2011年第30期3-4,共2页 China Practical Medicine

关键词舒利迭慢性阻塞性肺疾病稳定期疗效肺功能 Seretide CopD Sttionary phase Effect Lung function

分类号 R563.9 [医药卫生—呼吸系统]

引文网络
相关文献

参考文献6

1赵蓉雅,朱蕾.慢性阻塞性肺疾病流行病学及危险因素研究进展[J].国际呼吸杂志,2009,29(15):937-940. 被引量：13
2Fritscher L, Chapman, Chapaman KIL Seretide: a pharmacoeco- nomic analysis. Med Econ,2008,11 (3) :555 -570.
3Jones PW. Edin HM, Anderson J, Selmetemn/fluticasone pro-pio- nate combination improves health status in COPD patients. Am J Crit Ca re Med,2002,165(8 Supple) :111.
4Menezes AM, Perez-PadiUa R, ]ardim JR, et al. Chronic obstreu- tive pulmonary disease in five Latin Amerocan cities( the PLATINO study ) : a prevalence study. Lacent ,2005,366 (9500) : 1875 -1881.
5杨文杰,陶家驹,陈宝元.联合吸入糖皮质激素和长效β2-受体激动剂在慢性阻塞性肺疾病中的应用价值[J].国际呼吸杂志,2006,26(3):192-195. 被引量：50
6Watkins M, Wire P, Yates J, et aL Sustained FEV1 increase in COPD patients induced by salmeterol 50 mcg twice daily via the Diskus inhaler. Am J Besp Crit Care Med, 2002, 165 (8 supple) :228.

二级参考文献49

1储德节,孙书明,胡志雄,洪燕,徐坚.肺炎衣原体与慢性阻塞性肺疾病相关性[J].中国感染与化疗杂志,2008,8(4):260-265. 被引量：11
2严沛元.慢性阻塞性肺疾病急性加重期痰培养及临床分析[J].现代中西医结合杂志,2007,16(2):184-185. 被引量：3
3Schirnhofer L, Lamprecht B, Vollmer WM, et al. COPD prevalence in Salzburg, Austria: results from the Burden of Obstructive Lung Disease (BOLD) Study. Chest, 2007,131 29-36.
4Kim DS, Kim YS, Jung KS, et al. Prevalence of chronic obstructive pulmonary disease in Korea: a population-based spirometry survey. Am J Respir Crit Care Med, 2005, 172: 842-847.
5Zhong N, Wang C, Yao W, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med, 2007, 176: 753- 760.
6Talamo C,de Oca MM, Halbert R, et al. Diagnostic labeling of COPD in five Latin American cities. Chest, 2007,131 : 60-67.
7Halbert RJ ,Natoli lL,Gano A,et al. Global burden of COPD: systematic review andmeta-analysis. Eur Respir J, 2006,28 : 523-532.
8Falaschetti E, Laiho J, Primatesta P, et al. Prediction equations for normal and low lung function from the Health Survey for England. Eur Respir J, 2004,23 : 456-463.
9Shahab L,Jarvis MJ, Britton J, et al. Prevalence,diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. Thorax, 2006,61 : 1043-1047.
10Garcia-Aymerich J,Lange P, Benet M, et al. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic ohstructive pulmonary disease: a population-based cohort study. Am J Respir Crit Care Med, 2007,175 : 458-463.